Thorsteinn Thorsteinsson

20070015174, Jan 18, 2007

Jan 25, 2006

11/339294

Matthew Duan - Lisle IL, US
Charles McDermott - Encinitas CA, US
Aaron Hoffman - New Haven CT, US
Lansing Stewart - Bainbridge Island WA, US
Thorsteinn Thorsteinsson - Crest Hill IL, US
Robert O'Fee - New Hope PA, US
David Zembower - LaGrange IL, US

C12Q 1/68
G01N 33/53

435006000, 435007100

Methods for screening compounds for their solubility and their solution stability in a variety of diverse formulations and sets of diverse formulations useful for screening compounds for their solubility and their solution stability.

20080125477, May 29, 2008

May 15, 2007

11/748897

Jasbir Singh - Naperville IL, US
Matt Shaoming Duan - Foster City CA, US
Thorsteinn Thorsteinsson - Greensboro NC, US
Mitchell B. Friedman - Buffalo Grove IL, US
Mark Gurney - Grand Rapids MI, US

DECODE GENETICS, EHF. - Reykjavik

A61K 31/404
A61P 31/00
A61P 19/00
A61P 3/00
A61P 15/00
A61P 25/00
A61P 11/00

514414

The present invention is directed to pharmaceutical compositions of 7-(acryloyl)indoles, such as 4,5 -Dichloro-thiophene-2-sulfonic acid [(E)-3-[1-(2,4-dichlorophenylmethyl)-5-fluoro-3-methyl-1H-indol-7-yl]-acryloyl]amide (DTSI), having a structure shown below.The invention is also directed to methods of treatment utilizing formulations of the DTSI and processes of preparation of the formulations.

20110064806, Mar 17, 2011

Sep 2, 2010

12/874455

Dharma Rao Polisetti - High Point NC, US
Eric Benjamin - Jamestown NC, US
Thorsteinn Thorsteinsson - Jamestown NC, US

TransTech Pharma, Inc. - High Point NC

A61K 9/20
A61K 31/5383
A61P 3/10
A61P 5/50
C07D 498/14

424465, 5142298, 544101

The invention provides solid compositions comprising (S)-3-(4′-Cyano-biphenyl-4-yl)-2-{[(3S,7S)-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-1-methyl-2-oxo-6-((S)-1-phenyl-propyl)-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl]-amino}-propionic acid (OC-1) or a salt thereof and methods of making and using those compositions. The invention also provides the monohydrochloride salt of (S)-3-(4′-Cyano-biphenyl-4-yl)-2-{[(3S,7S)-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-1-methyl-2-oxo-6-((S)-1-phenyl-propyl)-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl]-amino}-propionic acid.

20060025380, Feb 2, 2006

Oct 18, 2005

11/127400

Thorsteinn Thorsteinsson - Minooka IL, US
Matthew Duan - Lisle IL, US
Robert O'Fee - New Hope PA, US

A61K 31/724
A61K 31/4172
A61K 31/405
A61K 31/401
A61K 31/198

514058000, 514419000, 514400000, 514423000, 514561000, 514567000, 514562000, 514565000, 514566000

A novel system for non-parenteral formulations comprising cyclodextrins is disclosed. The system includes hydrophobic cyclodextrins and amino acids and homo- or co-polymers thereof. The cyclodextrins and amino acids form a complex with pharmaceutical and other ingredients to achieve greatly improved solubility and/or enhance stability. The complexes can be used for delivery to mammals in a wide variety of non-parenteral formulations.

20220233701, Jul 28, 2022

Sep 21, 2021

17/480856

- High Point NC, US
Thorsteinn Thorsteinsson - Boynton Beach FL, US
Siva Kumar Rapuru - Jamestown NC, US

A61K 47/38
A61K 9/46
A61K 9/16
A61K 9/20
A61K 31/426
A61K 9/00
A61K 47/02
A61K 47/20
A61K 47/22
A61K 47/26

The invention relates to solid compositions comprising {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid, and methods of making and using such solid compositions.

20210322359, Oct 21, 2021

Jan 19, 2021

17/152103

- RIVIERA BEACH FL, US
Thorsteinn Thorsteinsson - Riviera Beach FL, US
Miguel Lopez-Toledano - Riviera Beach FL, US
Ahmed Abd Almalik Ahmed Mohammed Daak - Riviera Beach FL, US

MICELLE BIOPHARMA, INC. - RIVIERA BEACH FL

A61K 31/232
A61K 9/107
A61K 9/48
A61K 31/05
A61K 31/201
A61K 31/202
A61K 31/353
A61K 31/355
A61K 31/7024
A61K 47/10
A61K 47/26

Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect. The compositions are useful for treating certain disease states which may include (1) malabsorption syndromes, (2) primary sclerosing cholangitis (PSC), (3) non-alcoholic fatty liver disease (NAFLD), (4) sickle cell disease (SCD), (5) age-related macular degeneration (AMD), and (6) neurodegenerative disease, including, Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Epilepsy, Bi-polar Syndrome, traumatic brain injury, peripheral neuropathy, and Multiple Sclerosis (MS). Described are also various dosage forms for administering the compositions and use of the compositions in functional foods. Provided herein are also kits with instructions for their administration.

20210322360, Oct 21, 2021

Jan 25, 2021

17/156824

- Riviera Beach FL, US
Thorsteinn Thorsteinsson - Riviera Beach FL, US
Miguel Lopez-Toledano - Riviera Beach FL, US
Ahmed Abd Almalik Ahmed Mohammed Daak - Riviera Beach FL, US

MICELLE BIOPHARMA, INC. - Riviera Beach FL

A61K 31/232
A61K 9/107
A61K 9/48
A61K 31/05
A61K 31/201
A61K 31/202
A61K 31/353
A61K 31/355
A61K 31/7024
A61K 47/10
A61K 47/26

Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect. The compositions are useful for treating certain disease states which may include (1) malabsorption syndromes, (2) primary sclerosing cholangitis (PSC), (3) non-alcoholic fatty liver disease (NAFLD), (4) sickle cell disease (SCD), (5) age-related macular degeneration (AMD), and (6) neurodegenerative disease, including, Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Epilepsy, Bi-polar Syndrome, traumatic brain injury, peripheral neuropathy, and Multiple Sclerosis (MS). Described are also various dosage forms for administering the compositions and use of the compositions in functional foods. Provided herein are also kits with instructions for their administration.

20210244747, Aug 12, 2021

Feb 5, 2021

17/169103

- Boca Raton FL, US
Annette Shadiack - Somerset NJ, US
Thorsteinn THORSTEINSSON - Boynton Beach FL, US
Peter H.R. PERSICANER - Boca Raton FL, US

A61K 31/565
A61K 9/00
A61K 9/48

This disclosure provides pharmaceutical compositions for delivering estradiol to a subject in need thereof, as well as methods of administering the compositions, and methods of using them.